Abstract:The clinical progression of small-cell lung cancer (SCLC) remains pessimistic. The aim of the present study was to promote the understanding of the clinical significance and mechanism of O-linked N-acetylglucosamine (GlcNAc) transferase (OGT) in SCLC. Wilcoxon tests, standardized mean difference (SMD), and Kruskal–Wallis tests were utilized to compare OGT level differences among the experimental and control groups. The univariate Cox regression analysis, Kaplan–Meier curves, and receiver operating characteristic curves were applied to determine OGT’s clinical relevance in cancers. The Spearman correlation analysis and enrichment analysis were utilized to explore the underlying mechanisms of OGT in cancers. For the first time in the field, we provide an overview of OGT in 32 cancers using a large number of samples (n = 21,196), determining distinct OGT expression in 25 cancers and its prognosis effects in 12 cancers. Furthermore, using 950 samples from multiple sources, upregulated OGT was found in both mRNA and protein levels in SCLC (SMD = 0.93, 95% CI [0.24, 1.63]). Higher OGT levels represented a more unfavorable disease-free interval for SCLC patients ( p < 0.001 ). The research also identified OGT expression as a potential marker for SCLC prediction (sensitivity = 0.79, specificity = 0.86, and AUC = 0.88). The high expression of OGT in SCLC may result from the positive regulation of two transcription factors—DEK and XRN2. We primarily investigated the underlying mechanisms of OGT in SCLC. Herein, based on the analyses from pan-cancer to SCLC, OGT demonstrated conspicuous clinical significance. OGT may be an underlying biomarker for the treatment and identification of some cancers, including SCLC.

Regulation and Clinical Significance of O-GlcNAc Transferase in Cancer

Regulation of cancer metabolism by O-GlcNAcylation

O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling

The roles of OGT and its mechanisms in cancer

Tumor and Serum Gamma-Glutamyl Transpeptidase, New Prognostic and Molecular Interpretation of an Old Biomarker in Gastric Cancer

O-GlcNAcylation in cancer development and immunotherapy

O-GlcNAcylation in tumorigenesis and its implications for cancer therapy

Suppressed OGT Expression Inhibits Cell Proliferation and Modulates EGFR Expression in Renal Cell Carcinoma

O-GlcNAcylation: an Important Post-Translational Modification and a Potential Therapeutic Target for Cancer Therapy

Ogt Demonstrated Conspicuous Clinical Significance in Cancers, from Pan-Cancer to Small-Cell Lung Cancer

O-linked N-acetylglucosamine Transferase (OGT) is Overexpressed and Promotes O-linked Protein Glycosylation in Esophageal Squamous Cell Carcinoma

O‐GlcNAcylation of CSNK2A1 by OGT is Involved in the Progression of Colorectal Cancer

Can O-GIcNAc Transferase (OGT) Complex Be Used as a Target for the Treatment of Hematological Malignancies?

O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications

Functional Analysis of O-GlcNAcylation in Cancer Metastasis

O-GlcNAcylation of the Signaling Scaffold Protein, GNB2L1 Promotes Its Degradation and Increases Metastasis of Gastric Tumours.

Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling

Sugt1 Regulates the Progression of Ovarian Cancer Through the Akt/Pi3k/Mtor Signaling Pathway

Targeting O -GlcNAcylation in cancer therapeutic resistance: The sugar Saga continues

O‐GlcNAc transferase activates stem‐like cell potential in hepatocarcinoma through O‐GlcNAcylation of eukaryotic initiation factor 4E

Upregulation of OGT by Caveolin‐1 promotes hepatocellular carcinoma cell migration and invasion